Assessment of Device for Treatment of Amblyopia

The study will evaluate the effect of Reviview™, a dichoptic video display device for administrating a novel treatment protocol for Amblyopia (lazy eye) in kids.

The effect of the treatment will be measured by the change from baseline in Visual acuity and in Stereoscopic Vision; and to assess the ease of use of and compliance by the patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Amblyopia Brain Diseases Central Nervous System Diseases Eye Diseases Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Sensation Disorders Signs and Symptoms Vision Disorders

Age range

4 year–8 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tel-Aviv Sourasky Medical Center

Tel Aviv, Israel

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Refractive or Strabismic Amblyopia, with best corrected visual acuity.

(1) Refractive Amblyopia, visual acuity score <6:15 (worse then)

or (2) Strabismic Amblyopia, visual acuity score between 6:15 and 6:30

Exclusion criteria

Diagnosed with epilepsy, recently treated with occlusion or penalization therapy

Treatment and study plan

Daily watching videos using Reviview™, a dichoptic video display device, for 60 min

Device

Primary outcomes

Improvement in VA in amblyopic eye

Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Visior Technologies Ltd.

Industry

Registry information

Important dates

Study start: 2013
Primary completion: 2017
Study completion: 2017
First posted: Dec 6, 2013
Registry last updated: Jul 21, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed